Prospective study of EGFR intron 1 (CA)n repeats variants as predictors of benefit from cetuximab and irinotecan in chemo-refractory metastatic colorectal cancer (mCRC) patients.
Loupakis F, Antoniotti C, Cremolini C, Zhang W, Yang D, Wakatsuki T, Bohanes P, Schirripa M, Salvatore L, Masi G, Ricci V, Graziano F, Ruzzo A, Benhaim L, Marmorino F, Ning Y, El-Khoueiry R, Falcone A, Lenz HJ.
Loupakis F, et al. Among authors: yang d.
Pharmacogenomics J. 2014 Aug;14(4):322-7. doi: 10.1038/tpj.2014.1. Epub 2014 Feb 11.
Pharmacogenomics J. 2014.
PMID: 24513691